Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 10/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 10/20 | 0.57 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5656480 | 0.92 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL5658701 | 0.89 | CHRNB2 (0.59) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL5656340 | 0.86 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL6094605 | 0.80 | CHRNB2 (0.78) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL5659098 | 0.78 | CHRNB2 (0.59) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL5656491 | 0.78 | CHRNB2 (0.76) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL5655329 | 0.78 | CHRNB2 (0.76) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL5657086 | 0.78 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL5658189 | 0.76 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL15943652 | 0.76 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNA1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100192-A1 | Heteroaryl diazacycloalkanes, their preparation and use | DANPET AB (SE) | 2006-05-11 | — | — | US | claimed |
| US-20020045618-A1 | Heteroaryl diazacycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2002-04-18 | — | — | US | claimed |
| US-7282494-B2 | Heteroaryl diazacycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2007-10-16 | — | — | US | disclosed |
| US-20060100192-A1 | Heteroaryl diazacycloalkanes, their preparation and use | DANPET AB (SE) | 2006-05-11 | — | — | US | disclosed |
| US-20020045618-A1 | Heteroaryl diazacycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045618-A1 | Heteroaryl diazacycloalkanes, their preparation and use | CHRNA5, CHRNA7, CHRNA3 | CHRNB2 7/4885CHRNA4 12/4885CHRNA1 6/4885 |
| US-20060100192-A1 | Heteroaryl diazacycloalkanes, their preparation and use | CHRNA5, CHRNA7, CHRNA3 | CHRNB2 10/4885CHRNA4 9/4885CHRNA1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.